Does the UPC serve up new feeding grounds for US non-practising entities?

Well-resourced NPEs looking to play the injunction card are eyeing up the court—companies with European operations should prepare, say Tom Oliver and Jessica Rosethorn of Powell Gilbert.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Unified Patent Court

Regeneron and CureVac: UPC ‘cannot be ignored’

4 November 2025 Growing clout, powerful remedies, and efficiency are making the UPC a game-changer in global litigation, according to LSPN Europe experts. Tom Phillips reports.

Unified Patent Court

Abbott v Sibio: A game-changer for UPC tech disputes

27 February 2025 The UPC Court of Appeal’s approach to delivering a preliminary injunction in a glucose sensor dispute has far-reaching effects, as Wouter Pors of Bird & Bird explains.

Unified Patent Court

'A very good decision’: Patent industry welcomes UPC in-house reps update

13 February 2025 Court of Appeal says in-house representatives can appear before the court | Patent attorneys with ‘administrative and financial powers’ or shares remain barred | Decision specific to Microsoft v Suinno Mobile & AI Technologies Licensing.

More features

PTAB year in review: A shifting landscape and outlook for 2026

UPC: A review of 2025 and what to expect in 2026

From Edwards to Insulet: Three key medical device cases of 2025

Edwards v Meril: Behind the UPC’s landmark medtech showdown

5 ways the USPTO director is changing US innovation

Mirum targets generics in quartet of suits over liver treatment

Hogan Lovells and Cadwalader strike historic deal to create $3.6bn firm

Edwards v Meril: 3 insights from the UPC Court of Appeal’s decision

Does the UPC serve up new feeding grounds for US non-practising entities?

More on this story

Editor's picks

Editor's picks

More features